Back to Authors

Villà, S.

https://orcid.org/0000-0002-9089-4807

Mayo Clinic

Institut Català d'Oncologia

Citations 3

Reply to “Proper tumor classification and growth rate are key elements when considering indications and results of radiotherapy for head and neck paragangliomas”
Lassen–Ramshad, Yasmin , Özyar, Enis , Alanyalı, Senem , Poortmans, Philip , Houtte, Paul Van , Sohawon, Schoeb, Esassolak, Mustafa , Krengli, Marco , Miller, Robert C. , Demiroz, C. , Akyürek, Serap , Aggerholm‐Pedersen, Ninna , Villà, S. , Thariat, Juliette

Head & Neck | May 6, 2019 | Volume: 41 | Issue: 8 | Pages: 2837-2838

10.1002/hed.25800 Get It

Paraganglioma of the head and neck region, treated with radiation therapy, a Rare Cancer Network study
Lassen–Ramshad, Yasmin , Özyar, Enis , Alanyalı, Senem , Poortmans, Philip , Houtte, Paul Van , Sohawon, Schoeb, Esassolak, Mustafa , Krengli, Marco , Miller, Robert C. , Demiroz, C. , Akyürek, Serap , Aggerholm‐Pedersen, Ninna , Villà, S. , Thariat, Juliette

Head & Neck | January 11, 2019 | Volume: 41 | Issue: 6 | Pages: 1770-1776

10.1002/hed.25611 Get It

Abstract Background Paraganglioma of the head and neck (HNPGL) are rare often benign tumors. Surgery and radiation therapy (RT) are the main treatment choices. We present an analysis of outcome and toxicity after RT from 13 institutions of the Rare Cancer Network. Methods Data were collected using a questionnaire concerning patients' characteristics, treatment, and outcome. A total of 81 patients with 82 HNPGL were analyzed. Results The median follow‐up was 48 months (1‐456). Sixty‐two lesions were treated with conventional RT and 20 lesions with stereotactic RT. Local control (LC) was achieved in 69 out of 77 lesions. Late toxicity occurred in 17 patients. Patients treated with stereotactic RT experienced neither disease progression nor late toxicity. Four patients with a follow‐up longer than 20 years experienced disease progression. Conclusion RT for HNPGL offered good local control with acceptable toxicity. Stereotactic RT might offer better results. Long‐term follow‐up is required.
History of the Rare Cancer Network and past Research
Mirimanoff, René-Olivier, Özşahin, Mahmut , Thariat, Juliette , Özyar, Enis , Schick, Ulrike , Pehlivan, Berrin , Krengli, Marco , Franzetti-Pellanda, Alessandra , Vees, Hansjörg, Scandolaro, Luciano , Belkacémi, Yazid , Villà, S. , İğdem, Şefik , Lutsyk, Myroslav, Miller, Robert C. , Mirimanoff, R.O., Cai, Ling , Thariat, Juliette

Rare Tumors | November 7, 2014 | Volume: 6 | Issue: 3 | Pages: 86-90

10.4081/rt.2014.5462 Get It

Approximately, twenty years ago, the Rare Cancer Network (RCN) was formed in Lausanne, Switzerland, to support the study of rare malignancies. The RCN has grown over the years and now includes 130 investigators from twenty-four nations on six continents. The network held its first international symposium in Nice, France, on March 21-22, 2014. The proceedings of that meeting are presented in two companion papers. This manuscript reviews the history of the growth of the RCN and contains the abstracts of fourteen oral presentations made at the meeting of prior RCN studies. From 1993 to 2014, 74 RCN studies have been initiated, of which 54 were completed, 10 are in progress or under analysis, and 9 were stopped due to poor accrual. Forty-four peer reviewed publications have been written on behalf of the RCN.